Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT in Advanced Biliary Tract Cancer
NCT07890506Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, benmelstobart in biliary tract cancer (BTC), sponsored by Nanjing Drum-Tower Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tucidinostatbenmelstobart
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07890506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890506.